Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia.

Saved in:

Bibliographic Details
Title:	Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia.
Authors:	Williams, R., Kopala, L., Malla, A., Smith, G., Love, L., Balshaw, R.
Source:	Acta Psychiatrica Scandinavica. Supplementum. May2006 Supplement 430, Vol. 113, p12-21. 10p. 1 Diagram, 12 Charts, 1 Graph.
Subjects:	Health outcome assessment, Schizophrenia, Clozapine, Risperidone, Olanzapine, Antipsychotic agents
Geographic Terms:	Canada
Abstract:	Objective: To evaluate over a 2-year period, patients from academic/non-academic centres, from each region of Canada, to determine whether location or other variables such as medication type, gender or income was associated with outcome as defined by non-hospitalization and persistence on original treatment. Method: A total of 448 patients were recruited from academic and non-academic centres across all provinces of Canada and followed up for 2 years. Results: Patients from British Columbia had significantly lower rates of hospitalization than patients from other provinces. Male patients showed greater symptomatic improvement at 2 years from initial assessment compared to females. Patients on clozapine, risperidone and olanzapine were least likely to be hospitalized. Conclusion: There were some regional differences noted in both utilization of types of antipsychotic medications and hospitalization rates. In this sample of stable out-patients over 70% who started on monotherapy with clozapine, risperidone, olanzapine and quetiapine remained on the same medication over the 2-year study period. [ABSTRACT FROM AUTHOR]
	Copyright of Acta Psychiatrica Scandinavica. Supplementum is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	Psychology and Behavioral Sciences Collection

Description
Abstract:	Objective: To evaluate over a 2-year period, patients from academic/non-academic centres, from each region of Canada, to determine whether location or other variables such as medication type, gender or income was associated with outcome as defined by non-hospitalization and persistence on original treatment. Method: A total of 448 patients were recruited from academic and non-academic centres across all provinces of Canada and followed up for 2 years. Results: Patients from British Columbia had significantly lower rates of hospitalization than patients from other provinces. Male patients showed greater symptomatic improvement at 2 years from initial assessment compared to females. Patients on clozapine, risperidone and olanzapine were least likely to be hospitalized. Conclusion: There were some regional differences noted in both utilization of types of antipsychotic medications and hospitalization rates. In this sample of stable out-patients over 70% who started on monotherapy with clozapine, risperidone, olanzapine and quetiapine remained on the same medication over the 2-year study period. [ABSTRACT FROM AUTHOR]
ISSN:	00651591
DOI:	10.1111/j.1600-0447.2006.00757.x